Present Status of Anticoagulant Therapy in the Treatment of Myocardial Infarction; The Use and Misuse of Anticoagulants; An Evaluation of New Anticoagulants, Their Indications and Dosage

Article1 November 1955PRESENT STATUS OF ANTICOAGULANT THERAPY IN THE TREATMENT OF MYOCARDIAL INFARCTION; THE USE AND MISUSE OF ANTICOAGULANTS; AN EVALUATION OF NEW ANTICOAGULANTS, THEIR INDICATIONS AND DOSAGEIRVING S. WRIGHT, M.D., F.A.C.P.IRVING S. WRIGHT, M.D., F.A.C.P.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-43-5-942 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe use of anticoagulant therapy in the treatment of myocardial infarction is rapidly becoming accepted in medical centers and leading hospitals throughout the civilized world.1It is also being used well in many small communities where there exists the fortunate combination of a well trained, conscientious physician and a good laboratory capable of performing accurate prothrombin time tests.2While the report of the Committee on Anticoagulants of The American Heart Association constitutes the most comprehensive and detailed evaluation of this therapy, reports from more than 40 institutions confirming this study have appeared from the United States and foreign countries. In...Bibliography1. Thrombosis and embolism. I. International Conference, Basel, 1954, edited by T. Koller, and W. R. Merz, 1955, Benno Schwabe clinical evaluation of a new anticoagulant, Circulation 11: 576-583 (Apr.) 1955. CrossrefMedlineGoogle Scholar39. SorensonWright CWIS: A synthetic anticoagulant: a polysulfuric acid ester of polyanhydromannuronic acid (Paritol), Circulation 2: 658, 1950. CrossrefMedlineGoogle Scholar40. HirschboeckMadison JSFW: A comparison of the anticoagulant properties of a polyhexuronic acid ester with sodium heparin, J. Lab. and Clin. Med. 36: 836, 1950. MedlineGoogle Scholar41. SheppardBourgainSymonsWright ERCIS: The effect of phosphorylated and sulfonated hesperidin on blood coagulation, Arch. Biochem. and Biophys. 50: 224 (May) 1954. CrossrefMedlineGoogle Scholar42. SheppardImperanteWright EJIS: The effect of phosphorylated hesperidin on the polymerization of fibrinogen as studied by light-scattering, J. Biol. Chem. 212: 837 (Feb.) 1955. CrossrefMedlineGoogle Scholar43. BourgainSymonsToddWright RCMIS: The action of phosphorylated hesperidin on blood coagulation, J. Pharmacol. and Exper. Therap. 112: 393 (Dec.) 1954. MedlineGoogle Scholar44. InnerfieldSchwartzAngrist IAA: Intravenous trypsin—its anticoagulant, fibrinolytic thrombolytic effects, J. Clin. Investigation 31: 1049, 1952. CrossrefMedlineGoogle Scholar45. Tagnon JJ: Effect of intravenous injection of trypsin on the blood coagulation time in hemophilia, Proc. Soc. Exper. Biol. and Med. 57: 45, 1944. CrossrefGoogle Scholar46. TaylorOvermanWright ARSIS: Studies with crystalline trypsin. Results and hazards of intravenous administration and its postulated role in blood coagulation, J. A. M. A. 155: 347-351, 1954. CrossrefMedlineGoogle Scholar47. TaylorWright AIS: Intravenous trypsin, Circulation 10: 331-337 (Sept.) 1954. CrossrefMedlineGoogle Scholar48. LiebermanTaylorWright JSAIS: The effect of intravenous trypsin administration on the electrocardiogram of the rabbit, Circulation 10: 338-342 (Sept.) 1954. CrossrefMedlineGoogle Scholar49. FisherWilensky MMND: Parenteral trypsin in peripheral vascular and thromboembolic diseases, New York State J. Med. 54: 659-662 (Mar. 1) 1954. MedlineGoogle Scholar50. ClifftonCannamela EED: Fibrinolytic and proteolytic activity of a human "plasminogen," prepared from fraction III of human plasma, J. Appl. Physiol. 6: 42-50 (July) 1953. CrossrefMedlineGoogle Scholar51. ClifftonCannamelaGrossi EEDC: In vivo studies of human plasmin. Intravenous injection in dogs and rabbits, J. Appl. Physiol. 6: 143-150 (Sept.) 1953. CrossrefMedlineGoogle Scholar52. ClifftonGrossiCannamela EECD: Lysis of thrombi produced by sodium morrhuate in the femoral vein of dogs by human plasmin (fibrinolysin), Ann. Surg. 139: 52-62 (Jan.) 1954. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: New York, N. Y.*From the Symposium on Acute Myocardial Infarction, presented at the Thirty-sixth Annual Session of The American College of Physicians, Philadelphia, Pennsylvania, April 26, 1955.From the Cornell University Medical College, New York, N. Y.Aided by grants from the Kress, Lasker, Hampil and Hyde Foundations. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byGeneral AspectsClinical Applications of AspirinWhy we should not skip aspirin in cardiovascular preventionPsychological Aspects of Coronary Heart DiseaseThe Physician's Responsibility in the Age of Therapeutic PlentyAnticoagulant Treatment in Acute Coronary Occlusion with "So-Called" Ischemic PatternAnticoagulation Therapy TodayORAL AND INTRAVENOUS ESTROGENS IN THE TREATMENT AND PREVENTION OF BLEEDING ASSOCIATED WITH LONG-TERM ANTICOAGULANT THERAPYHeparin Administration after Acute Myocardial InfarctionDie Coronarerkrankungen. Coronarinsuffizienz, Angina pectoris und HerzinfarktDicumarol, Coumadin, Marcumar and TromexanPhenprocoumon (marcumar)∗Clinical Evaluation of a New Oral Anticoagulant "Sintrom"Intramuscular Injection of Trypsin: Its Value as a Thrombolytic and Anti-Inflammatory AgentAnticoagulant therapy in coronary artery diseaseThe Treatment of Cerebrovascular AccidentTHE EFFECTIVENESS OF AN ORAL VITAMIN K1 IN CONTROLLING EXCESSIVE HYPOPROTHROMBINEMIA DURING ANTICOAGULANT THERAPY*STUART W. COSGRIFF, M.D.The present status of anticoagulants 1 November 1955Volume 43, Issue 5Page: 942-954KeywordsAcute myocardial infarctionAnticoagulant therapyAnticoagulantsHeartHemorrhageLongitudinal studiesMyocardial infarctionPatientsProthrombin timeResearch laboratories ePublished: 1 December 2008 Issue Published: 1 November 1955 PDF downloadLoading ...